Journal of Nuclear Medicine: 195-Patient Study Finds SSTR Expression Largely Retained After PRRT Progression, Supporting Retreatment
A Journal of Nuclear Medicine study analyzed patterns of progression in 195 patients with gastroenteropancreatic neuroendocrine tumors treated with [177Lu]Lu-DOTATATE PRRT. Progression occurred in 107 patients (54.9%), most often in the liver (60.7%) followed by bone (25.3%). Post-progression somatostatin receptor PET imaging showed retained SSTR uptake in 59.7% of patients, increased uptake in 18.2%, and reduced uptake in 19.5%, indicating that the majority remain candidates for additional SSTR-targeted radioligand therapy. The dataset reinforces the clinical case for sequencing peptide radioligand therapies rather than abandoning the modality at first progression.